A carregar...
Combined assessment of early and late‐phase outcomes in orphan drug development
In drug development programs, proof‐of‐concept Phase II clinical trials typically have a biomarker as a primary outcome, or an outcome that can be observed with relatively short follow‐up. Subsequently, the Phase III clinical trials aim to demonstrate the treatment effect based on a clinical outcome...
Na minha lista:
| Publicado no: | Stat Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8252448/ https://ncbi.nlm.nih.gov/pubmed/33813759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/sim.8952 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|